These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 22004531)

  • 1. Costs and health resources utilization following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain: a post hoc analysis.
    Navarro A; Saldaña MT; Pérez C; Masramón X; Rejas J
    Pain Pract; 2012 Jun; 12(5):382-93. PubMed ID: 22004531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
    Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
    Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pain alleviation and patient-reported health outcomes following switching to pregabalin in individuals with gabapentin-refractory neuropathic pain in routine medical practice.
    Saldaña MT; Pérez C; Navarro A; Masramón X; Rejas J
    Clin Drug Investig; 2012 Jun; 32(6):401-12. PubMed ID: 22480279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
    J Eval Clin Pract; 2012 Dec; 18(6):1170-9. PubMed ID: 21883712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings.
    Navarro A; Saldaña MT; Pérez C; Torrades S; Rejas J
    BMC Neurol; 2011 Jan; 11():7. PubMed ID: 21251268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
    Udall M; Harnett J; Mardekian J
    J Med Econ; 2012; 15(2):361-70. PubMed ID: 22181052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics, pharmacotherapy and healthcare resource use among patients with fibromyalgia newly prescribed gabapentin or pregabalin.
    Gore M; Sadosky AB; Zlateva G; Clauw DJ
    Pain Pract; 2009; 9(5):363-74. PubMed ID: 19500273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.
    Pérez C; Navarro A; Saldaña MT; Masramón X; Pérez M; Rejas J
    Pain Med; 2013 Dec; 14(12):1954-63. PubMed ID: 24330229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness analysis of the effect of pregabalin versus usual care in the treatment of refractory neuropathic pain in routine medical practice in Spain.
    de Salas-Cansado M; Pérez C; Saldaña MT; Navarro A; Rejas J
    Pain Med; 2012 May; 13(5):699-710. PubMed ID: 22594706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
    Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
    Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.
    Sicras-Mainar A; Rejas-Gutiérrez J; Pérez-Páramo M; Navarro-Artieda R
    J Eval Clin Pract; 2017 Apr; 23(2):402-412. PubMed ID: 27671223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pregabalin in the treatment of refractory neck pain: cost and clinical evidence from medical practice in orthopedic surgery and rehabilitation clinics.
    Flórez-García M; Ceberio-Balda F; Morera-Domínguez C; Masramón X; Pérez M
    Pain Pract; 2011; 11(4):369-80. PubMed ID: 21199310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost savings associated with early initiation of pregabalin in the management of peripheral neuropathic pain.
    Pérez C; Navarro A; Saldaña MT; Figueras-Balsells M; Muñoz-Tudurí M; Rejas J
    Clin J Pain; 2013 Jun; 29(6):471-7. PubMed ID: 23328322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
    Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
    J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trigeminal neuralgia treated with pregabalin in family medicine settings: its effect on pain alleviation and cost reduction.
    Pérez C; Saldaña MT; Navarro A; Martínez S; Rejas J
    J Clin Pharmacol; 2009 May; 49(5):582-90. PubMed ID: 19299534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of pharmacoeconomic studies for pregabalin.
    Parker L; Huelin R; Khankhel Z; Wasiak R; Mould J
    Pain Pract; 2015 Jan; 15(1):82-94. PubMed ID: 24815038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin.
    Gore M; Tai KS; Zlateva G; Bala Chandran A; Leslie D
    Pain Pract; 2011; 11(6):528-39. PubMed ID: 21435162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost comparison of adding pregabalin or gabapentin for the first time to the therapy of patients with painful axial radiculopathy treated in Spain.
    Sicras-Mainar A; Rejas-Gutiérrez J; Navarro-Artieda R; Planas-Comes A
    Clin Exp Rheumatol; 2013; 31(3):372-81. PubMed ID: 23432967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings.
    Navarro A; Saldaña MT; Pérez C; Torrades S; Rejas J
    Pain Med; 2010 May; 11(5):719-31. PubMed ID: 20345618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
    Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
    Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.